The occurrence of postgonococcal urethritis (PGU) was studied in heterosexual men who were randomly assigned to receive either oral doxycycline 100 mg or a placebo capsule twice daily for seven days in addition to routine single dose treatment of urethral gonorrhoea. Of 
group and 30/112 (26.8%) in the doxycycline group. Symptomatic PGU was uncommon (6.7% in the placebo group, 2.7% in the doxycycline group). Persistence of chlamydial infection at first follow-up was associated with the development of PGU in the placebo group (p < 0.05). Although PGU developed in 10/12 (83%) patients in whom Mycoplasma hominis was isolated on entry to the study, the association was not statistically significant. The development of PGU was not associated with the isolation of Ureaplasma urealyticum. A significant reduction in the incidence of PGU was achieved by the addition of a course of doxycycline (p < 0 001), but there remained a considerable proportion of patients in whom the aetiology of PGU was unknown.
Postgonococcal urethritis (PGU) occurs after single dose treatment of urethral gonorrhoea in heterosexual men in 30% to 700o of patients, [1] [2] [3] but is less common in homosexual men.47 PGU may be associated with symptoms such as urethral discharge and/or dysuria, or may be asymptomatic when the diagnosis is based solely on the finding of excess polymorphonuclear leucocytes on a gram-stained urethral smear.
In the majority of studies the condition has been most commonly associated with the isolation of the genital serotypes of Chlamydia trachomatis from the urethra, presumably due to concomitant chlamydial infection. 6 phenol red and 15 jug/ml lincomycin (ureaplasma broth, pH 6.5). Thallous acetate (0.25%) was added only to the mycoplasma agar. Two urethral specimens were obtained using wire-mounted nasopharyngeal (calcium alginate) swabs. One swab was placed in transport medium and delivered to the laboratory within two hours. The swab was then plated on to mycoplasma agar before being expressed into arginine broth. Both cultures were incubated at 37°C for seven days, the agar in 5 % CO2 and the broth aerobically. The broth was subcultured on to mycoplasma agar if there was a colour change from orange to magenta. Typical "fried egg" colonies on the mycoplasma agar were regarded as positive for M hominis.
The second swab was expressed directly into ureaplasma broth and serial ten-fold dilutions made up to 1:1000. These were incubated aerobically at 37°C and examined over 72 hours for colour change from yellow to magenta. The highest dilution showing a colour change was subcultured on to blood agar to exclude contaminants. In the absence ofcontaminants such cultures were recorded as positive for U urealyticum.
ISOLATION OF GARDNERELLA VAGINALIS
Specimens were inoculated on to Human Blood Agar bi-layer plates with antibiotic selective supplement (gentamicin sulphate 4 mg/l medium, nalidixic acid 30 mg/l medium, amphotericin B 2 mg/l; Oxoid Ltd., Basingstoke, England) and incubated in an 8% CO2 atmosphere for 48 hours. Colonies that consisted of Gram-variable bacilli, showing beta-haemolysis on human but not horse blood agar, were catalasenegative, susceptible to metronidazole 50 pg disc (Oxoid) and resistant to sulphonamide 1,000 pg disc (Oxoid) were identified as G vaginalis.
TREATMENT AND FOLLOW UP Patients were given single dose treatment with oral ampicillin 3 g plus probenecid 1 g. Alternatively intramuscular spectinomycin 2 g was given if the patient was allergic to penicillin or infection with penicillinase-producing Neisseria gonorrhoeae (PPNG) was suspected on the basis of a history of sexual contact in an area with a high prevalence of PPNG infection, in particular the Far East or Central Africa. In addition patients were randomised by a computer generated code to receive either oral doxycycline 100 mg twice daily for seven days or one placebo capsule twice daily for seven days. This protocol was approved by the District Ethical Subcommittee.
Patients were asked to reattend for follow-up on the 14th day after initial presentation. Urethral specimens were taken for microscopy and for repeat cultures of N gonorrhoeae, C trachomatis, U urealyticum, M hominis and G vaginalis. A second follow-up was requested on day 28 when further urethral specimens were taken for microscopy and culture of N gonorrhoeae and serological tests for syphilis were repeated.
STATISTICAL ANALYSIS
Statistical correlates were calculated using the chisquare test with Yates's correction.
Results
Three hundred and thirty five patients were enrolled into the study. One hundred and nineteen of these were excluded from analysis because they failed to attend for initial follow-up tests (87), they failed to take the course of doxycycline or placebo capsules (11), or they were unable to be assessed for PGU because of persistence of gonococcal infection due to reinfection or treatment failure (21). Therefore 216 men were assessable for the presence of PGU at initial follow-up, 104 In the doxycycline group there was no association between the development of PGU and isolation of M hominis on entry (p > 0.5), persistence of M hominis at day 14 (p > 0.5), isolation of U urealyticum on entry (p > 0 5) nor persistence of U urealyticum at day 14 (p > 0.5). (Data not shown in table) .
Of 103 patients treated with doxycycline, 13 had persistence of U urealyticum at day 14.
G vaginalis was isolated on entry in only one patient in the study.
Discussion
The incidence of PGU in the placebo group was 52%, which falls within the range of 30 to 70% reported in previous studies.'`PGU was associated with symptoms in only 13% (7/54) of cases in this group. Failure to perform a urethral smear at day 14 and chlamydial testing on presentation would have resulted in 47 of 54 (87%) patients with microscopic PGU being untreated due to the absence of symptoms. Forty seven of 104 (45%) patients with gonorrhoea in the placebo group had asymptomatic PGU diagnosed at day 14. Therefore PGU will pass undiagnosed unless it is carefully sought, particularly in departments without adequate chlamydial diagnostic facilities. A course of doxycycline 100 mg taken twice daily for one week was associated with a highly significant reduction (p < 0-001) in the incidence of PGU (51 9% in the placebo group vs 26.8% in the doxycycline group). This supports the findings of Ridgway and Oriel who compared the effect of adding a course of oxytetracycline 500 mg orally four times daily for 7 days to single dose oral treatment for gonorrhoea with a historical group treated with ampicillin and probenecid alone.7 In their study PGU was diagnosed in nine (20%) of 45 patients treated with oxytetracycline in addition to ampicillin and probenecid. In our study 30 (27%) of 112 patients treated with doxycycline in addition to single dose treatment for gonorrhoea developed PGU. Therefore although the addition of doxycycline resulted in a significant reduction in the development of PGU, there remained a considerable proportion of patients who still developed PGU. In both studies the addition of a tetracycline resulted in almost complete elimination of C trachomatis at follow-up in patients positive on entry, so it would appear likely that PGU in this group is due to a cause other than C trachomatis.
The chlamydial isolation rate of 14% on entry to the study was lower than we had expected, but fell within the range of 11 to 34% reported in earlier studies. 59 Similarly the chlamydial isolation rate of 23% (12/52) on entry in patients in the placebo group who went on to develop PGU was lower than in some studies but within the reported range of 15 to 81% . 5 Isolation of M hominis on entry to the study was associated with the development ofPGU in 830% (10/ 12) of patients in the placebo group, but the association was not significant, and was reduced further after exclusion of three patients in whom C trachomatis was also isolated. Persistence ofM hominis at follow-up was associated with PGU in 80% (4/5) of cases, but the small numbers involved were not compatible with the demonstration of a significant difference. The addition of doxycycline was associated with a lower incidence of PGU (3/13, 23%) in patients with M hominis and persistence of the organism occurred in only two cases, neither of whom developed PGU.
These figures suggest an association of M hominis with PGU but statistical significance could not be shown. A larger group of patients would have to be studied in order to establish whether the association would reach significance.
Neither the initial isolation of U urealyticum nor the persistence of the organism was associated with the development of PGU. This finding is in accordance with earlier studies.2 G vaginalis was isolated in only one patient in the study.
We did not routinely examine urethral specimens for the presence of Trichomonas vaginalis as previous work has shown that this organism is rarely isolated in these patients. 8 This study confirms that a significant reduction in the incidence of PGU may be achieved by the addition of a course of tetracycline to standard single dose treatment for urethral gonorrhoea. There remains a considerable proportion of patients in whom the aetiology of PGU is unknown. 
